Headquartered in The Woodlands, TX Fiscal year ends December NASDAQ: LXRX lexpharma.com
Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives. The company's pipeline spans neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. Its commercial product, INPEFA (sotagliflozin), is approved in the U.S. for heart failure and is a unique oral dual SGLT1/SGLT2 inhibitor that has been studied in approximately 20,000 patients. Lexicon is also advancing ZYNQUISTA (sotagliflozin) toward NDA resubmission for type 1 diabetes, a disease with no approved treatments beyond insulin. The company's pipeline includes pilavapadin (LX9211), a selective AAK1 inhibitor for neuropathic pain, and LX9851, a first-in-class oral ACSL5 inhibitor licensed to Novo Nordisk for obesity and metabolic disorders. Lexicon has licensing partnerships with Novo Nordisk (LX9851 globally) and Viatris (sotagliflozin ex-U.S. and ex-Europe). Viatris has obtained regulatory approvals for heart failure in the UAE and Bahrain and has submitted applications in multiple additional markets. Updated
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…
Friday's additional top analyst upgrades and downgrades were on Ciena, Lennar, Lexicon Pharmaceuticals, Mister Car Wash, PagerDuty, RealReal, Six Flags and more.
The Friday afternoon analyst calls were focused on Biogen, 3D Systems, Duke Energy, Ford, and more.
Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
Chris Lange 24/7 Wall St. has compiled a list of some speculative biotech plays that could see gains of up to 300% in the coming months.
Lexicon Pharmaceuticals shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes.
Chris Lange After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.
Lexicon Pharma shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm.
Chris Lange Lexicon shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on the Marketing Authorization of Zynquista (sotagliflozin).
Chris Lange Vodafone, Lexicon Pharmaceuticals, Amneal Pharmaceuticals, and Maiden Holding had all posted new 52-week lows by noon Friday.
Immunomedics, Signet Jewelry, Nautilus, and Lexicon Pharmaceuticals had all posted new 52-week lows by noon Friday.
Lexicon shares fell on Friday after the FDA voted to approve the firm’s type 1 diabetes treatment. Although the result from this committee was mixed, it seems to be a case of…
Chris Lange Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
The top analyst upgrades, downgrades and other research calls from Monday include American Electric Power, American Water Works, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald's and Ulta Beauty.
Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives. The company's pipeline spans neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications.
The Wall Street consensus 12-month price target for LXRX is $4.55.
